{"organizations": [], "uuid": "49df182735c7e9db95a2f4c9fc4929d4e5308e86", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-cellular-biomedicine-announces-pos/brief-cellular-biomedicine-announces-positive-clinical-data-of-knee-osteoarthritis-china-phase-i-trial-idUSASC09SMI", "country": "US", "domain_rank": 408, "title": "BRIEF-Cellular Biomedicine Announces Positive Clinical Data Of Knee Osteoarthritis China Phase I Trial", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-03-16T13:15:00.000+02:00", "replies_count": 0, "uuid": "49df182735c7e9db95a2f4c9fc4929d4e5308e86"}, "author": "", "url": "https://www.reuters.com/article/brief-cellular-biomedicine-announces-pos/brief-cellular-biomedicine-announces-positive-clinical-data-of-knee-osteoarthritis-china-phase-i-trial-idUSASC09SMI", "ord_in_thread": 0, "title": "BRIEF-Cellular Biomedicine Announces Positive Clinical Data Of Knee Osteoarthritis China Phase I Trial", "locations": [], "entities": {"persons": [], "locations": [{"name": "u.s.", "sentiment": "none"}, {"name": "california", "sentiment": "none"}], "organizations": [{"name": "brief-cellular biomedicine announces positive clinical data of knee", "sentiment": "negative"}, {"name": "brief-cellular biomedicine announces positive clinical data of knee osteoarthritis china phase", "sentiment": "negative"}, {"name": "osteoarthritis china phase i trial reuters staff", "sentiment": "none"}, {"name": "min read   cellular biomedicine group inc", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": " 15 AM / Updated 13 minutes ago BRIEF-Cellular Biomedicine Announces Positive Clinical Data Of Knee Osteoarthritis China Phase I Trial Reuters Staff 2 Min Read   Cellular Biomedicine Group Inc : * CELLULAR BIOMEDICINE GROUP ANNOUNCES POSITIVE 48-WEEK CLINICAL DATA OF ALLOJOINâ„¢ HUMAN ADIPOSE-DERIVED MESENCHYMAL PROGENITOR CELL (HAMPC) KNEE OSTEOARTHRITIS (KOA) CHINA PHASE I TRIAL * CELLULAR BIOMEDICINE GROUP - STUDY SHOWED ALLOJOIN TO HAVE GOOD SAFETY TOLERANCE AND EARLY SIGNS OF EFFICACY IN PREVENTING CARTILAGE DETERIORATION * CELLULAR BIOMEDICINE - PRIMARY END POINT SHOWED A SIGNIFICANT IMPROVEMENT AT 12 WEEKS POST ALLOJOIN CELL THERAPY, CONTINUED IMPROVEMENT AT 48 WEEKS * CELLULAR BIOMEDICINE - SECONDARY END POINT SHOWED INCREASED TENDENCY VERSUS THAT AT BASELINE 0 WEEKS, VERSUS NORMAL CARTILAGE DETERIORATION AS RESULT OF AGING * CELLULAR BIOMEDICINE - DE-PRIORITIZING U.S. ALLOJOIN OPERATION & CALIFORNIA INSTITUTE OF REGENERATIVE MEDICINE PROJECT TERMINATED, EFFECTIVE MARCH 14 * CELLULAR BIOMEDICINE - COMMON SIDE EFFECTS WERE TEMPORARY LOCAL REACTIONS INCLUDING SORENESS, SWELLING AT INJECTION SITE IN STUDY * CELLULAR BIOMEDICINE GROUP INC - TO DATE, NO SERIOUS ADVERSE EVENTS RELATED TO ALLOJOIN THERAPY HAVE BEEN REPORTED * CELLULAR BIOMEDICINE- 2 PATIENTS WHO UNDERWENT ONE DOSE OF INJECTIONS DROPPED OUT OF STUDY AS THEIR KNEE JOINTS WERE MORE PAINFUL AFTER INJECTION Source text for Eikon:  ", "external_links": [], "published": "2018-03-16T13:15:00.000+02:00", "crawled": "2018-03-16T13:39:25.049+02:00", "highlightTitle": ""}